Work

Omalizumab Combined with Cyclosporine for the Treatment and Management of Refractory Urticarial Vasculitis

Year: 2026

Type: article

Abstract: Urticarial vasculitis (UV) is a clinicopathologic entity characterized by urticarial lesions disclosing histopatho logically leukocytoclastic vasculitis, mainly of postcapillary venules. A 61-year-old woman with a four-month history of widespread, pruritic urticarial lesions was diagnosed with urticarial vasculitis. The patient received a subcutaneous injection of Omalizumab (300 mg) every 28 days, combined with oral Cyclosporine (3 mg/kg/day). Significant clinical improvement was noted within five days post-treatment. This case highlights the difficulties in treating refractory urticarial vasculitis while demonstrating the successful use of Omalizumab plus Cyclosporine, providing a viable treatment option for similar patients.

Source: Clinical Cosmetic and Investigational Dermatology

DOI: 10.2147/ccid.s560845

Authors: Xinlong Chen, Qiao Yu, Degui Chang, Lisha Sun

Institution: Chengdu University of Traditional Chinese Medicine

Language: English

Topic: Urticaria and Related Conditions

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,836